Omeprazole (Monograph)

Brand names: PriLOSEC, Zegerid
Drug class: Proton-pump Inhibitors
- Antiulcer Agents
- Gastric Antisecretory Agents
- Acid-pump Inhibitors
VA class: GA900
Chemical name: 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
Molecular formula: C₁₇H₁₉N₃O₃SC₃₄H₃₆MgN₆O₆S₂
CAS number: 73590-58-6

Medically reviewed by Drugs.com on Feb 5, 2025. Written by ASHP.

Introduction

Acid- or proton-pump inhibitor; gastric antisecretory agent.¹ ² ³ ⁴ ⁵ ⁸ ¹³² ²⁰⁷ ²⁰⁸

Uses for Omeprazole

Gastroesophageal Reflux (GERD)

Short-term treatment of symptomatic GERD (e.g., heartburn).¹ ⁵ ⁹⁷ ²⁰⁷ ²⁰⁸

Short-term treatment of erosive esophagitis (endoscopically diagnosed) in patients with GERD.¹ ² ³ ⁴ ⁵ ⁸ ⁹² ⁹³ ⁹⁴ ⁹⁵ ⁹⁶ ⁹⁷ ⁹⁸ ²⁰⁷

Maintain healing and decrease recurrence of erosive esophagitis.¹ ⁹² ⁹³ ⁹⁴ ⁹⁵ ⁹⁶ ²⁰⁷ ²⁰⁸

Short-term self-medication for symptomatic relief of frequent (e.g., 2 or more days a week) heartburn in adults ≥18 years of age.¹⁸⁷

Duodenal Ulcer

Short-term treatment of active duodenal ulcer (endoscopically or radiographically confirmed).¹ ² ³ ⁴ ⁸ ²⁰⁷ ²⁰⁸

Treatment of Helicobacter pylori infection and duodenal ulcer disease.¹ ¹³⁸ Used in conjunction with amoxicillin and clarithromycin (triple therapy) or clarithromycin (dual therapy);¹ ¹³⁸ has been used in other multidrug regimens^{† [off-label]}.²⁷ ²⁸ ²⁹ ³⁷ ³⁸ ³⁹ ⁶¹ ⁶² ⁶⁶ ⁶⁷ ⁷⁵ ⁷⁶ ⁷⁷ ⁷⁸ ⁷⁹ ⁸¹ ⁸² ¹⁰⁶ ¹⁰⁸ ¹¹⁰ ¹¹¹ ¹¹² ¹¹³ ¹¹⁵ ¹³⁸

Gastric Ulcer

Short-term treatment and symptomatic relief of active benign gastric ulcer.¹ ²⁰⁷ ²⁰⁸

Crohn’s Disease-associated Ulcers

Some evidence for use of proton-pump inhibitors (e.g., omeprazole) for gastric acid suppressive therapy as an adjunct in the management of upper GI Crohn’s disease^{† [off-label]}, including esophageal, gastroduodenal, and jejunoileal disease.¹⁹⁰ ¹⁹¹ ¹⁹² ¹⁹⁴ ¹⁹⁵ ¹⁹⁶

Pathologic GI Hypersecretory Conditions

Long-term treatment of Zollinger-Ellison syndrome, multiple endocrine adenomas, or systemic mastocytosis in adults.¹ ² ³ ⁴ ⁵ ⁸ ¹³

Upper GI Bleeding

Used to decrease risk of upper GI bleeding in critically ill patients.²⁰⁷ ²⁰⁸ ²¹¹

Omeprazole Dosage and Administration

Administration

Omeprazole is acid-labile.¹ ²⁰⁷ ²⁰⁸ To avoid decomposition in acidic pH of the stomach, delayed-release capsules and delayed-release oral suspension (Prilosec) contain enteric-coated granules of the drug;¹ ² ⁴ immediate-release capsules and immediate-release oral suspension (Zegerid) contain sodium bicarbonate to protect the drug.²⁰⁷ ²⁰⁸

Oral Administration

Immediate-release Capsules

Swallow intact with a glass of water at least 1 hour prior to a meal.²⁰⁷ Do not use with any other liquid.²⁰⁷ Do not open capsules or mix the contents with food.²⁰⁷

Do not substitute two 20-mg capsules for one 40-mg capsule because the 20-mg and 40-mg capsules contain the same amount of sodium bicarbonate.²⁰⁷

Delayed-release Capsules

Administer orally at least 1 hour before a meal.¹

Swallow capsules intact; do not chew or crush.¹

Antacids may be used concomitantly as needed for pain relief.¹ ³

Alternatively, open capsule and mix contents with 1 tablespoon applesauce; swallow immediately without chewing and with glass of cool water to ensure complete swallowing.¹ Applesauce should not be hot and should be soft enough to swallow without chewing.¹

Delayed-release Tablets

Tablets for self-medication: swallow intact with a glass of water before breakfast; do not chew, crush, or crush in food.¹⁸⁷ ¹⁸⁹

Powder for Immediate-release Oral Suspension

Administer at least 1 hour prior to a meal.²⁰⁷ ²⁰⁸

May use antacids, antacid/alginic acid combinations, histamine H₂-receptor antagonists, or histamine H₂-receptor antagonist and antacid combinations for “breakthrough” symptoms, but efficacy of these preparations has not been established.²⁰⁸

Empty 20- or 40-mg single-dose packet for oral suspension into small cup containing 15–30 mL of water, stir well, and swallow immediately.²⁰⁷ ²⁰⁸ Rinse container with more water and swallow to ensure complete consumption of the dose.²⁰⁷ ²⁰⁸ Do not mix with any other liquid or food.²⁰⁷ ²⁰⁸

Do not substitute two 20-mg packets for one 40-mg packet because the 20- and 40-mg powder for oral suspension packets contain the same amount of sodium bicarbonate.²⁰⁷

Powder for Delayed-release Oral Suspension

Administer at least 1 hour before a meal.¹

Antacids may be used concomitantly.¹

Empty contents of 2.5- or 10-mg single-dose packet into small cup containing 5 or 15 mL, respectively, of water.¹ Stir well, then allow to thicken for 2–3 minutes.¹ Stir again and administer within 30 minutes of preparation.¹ If any material remains in the cup, add additional water, mix, and ingest immediately to ensure complete consumption of the dose.¹

NG Tube

Powder for delayed-release oral suspension: Reconstitute 2.5- or 10-mg single-dose packet with 5 or 15 mL of water, respectively, in a catheter-tipped syringe and shake immediately.¹ Allow mixture to thicken for 2–3 minutes.¹ Shake syringe and administer within 30 minutes through NG or gastric tube (6 French or larger).¹ Refill syringe with additional water (5 or 15 mL, respectively), shake, and flush any remaining drug mixture from the tube.¹

Powder for immediate-release oral suspension: Reconstitute 20- or 40-mg single-dose packet with 20 mL of water, stir well, administer immediately through NG or orogastric tube using appropriately sized syringe.²⁰⁷ ²⁰⁸ Flush the tube with 20 mL of water after administration.²⁰⁷ ²⁰⁸ Temporarily stop continuous enteral feeding via NG or orogastric tube for 3 hours before and 1 hour after administration.²⁰⁷ ²⁰⁸

Dosage

Available as omeprazole and omeprazole magnesium; dosage expressed in terms of omeprazole.¹ ¹⁸⁷

Pediatric Patients

Gastroesophageal Reflux

GERD.

Oral (Delayed-release Capsules or Delayed-release Oral Suspension)

Oral Omeprazole Dosage for Treatment of GERD in Pediatric Patients 1–16 Years of Age1
Body Weight	Omeprazole Dosage
5 to <10 kg	5 mg once daily
10 to <20 kg	10 mg once daily
≥20 kg	20 mg once daily

Administered for 4 weeks in one study.¹ ¹⁹⁸

Treatment of Erosive Esophagitis.

Oral (Delayed-release Capsules or Delayed-release Oral Suspension)

Oral Omeprazole Dosage for Treatment of Erosive Esophagitis in Pediatric Patients 1–16 Years of Age1
Body Weight	Omeprazole Dosage
5 to <10 kg	5 mg once daily
10 to <20 kg	10 mg once daily
≥20 kg	20 mg once daily

On a mg/kg basis, dosage of omeprazole required to heal erosive esophagitis is greater in children than that required in adults.¹ ¹⁹⁷ ¹⁹⁸ In an uncontrolled open-label study, dosages required for healing were 0.7–3.5 mg/kg daily (maximum 80 mg daily) for 3–6 months; about 90% of children healed in the first 3 months, and about 5% required a second course of treatment.¹ ¹⁹⁷ ¹⁹⁸ Dosage of 0.7 mg/kg daily resulted in healing in 44% of children; an additional 28% of the children studied required a dosage of 1.4 mg/kg daily for healing to occur.¹ ¹⁹⁷ ¹⁹⁸

Maintenance of Healing of Erosive Esophagitis.

Oral (Delayed-release Capsules or Delayed-release Oral Suspension)

Oral Omeprazole Dosage for Maintenance Therapy in Pediatric Patients 1–16 Years of Age1
Body Weight	Omeprazole Dosage
5 to <10 kg	5 mg once daily
10 to <20 kg	10 mg once daily
≥20 kg	20 mg once daily

Maintenance therapy continued 2 years in one study.¹ ¹⁹⁸ In an uncontrolled open-label study, maintenance dosages were half the dosages required for initial healing in 54% of children, while 46% required dosage increase (0.7–2.8 mg/kg daily) for all or part of the study.¹ ¹⁹⁸

Adults

GERD

GERD without Erosive Esophagitis

Oral (Immediate-release Capsules or Oral Suspension, Delayed-release Capsules or Oral Suspension)

20 mg once daily for up to 4 weeks.¹ ² ²⁰⁷ ²⁰⁸

Treatment of Erosive Esophagitis

Oral (Immediate-release Capsules or Oral Suspension, Delayed-release Capsules or Oral Suspension)

20 mg once daily until healing occurs (usually within 4–8 weeks);¹ ² ²⁰⁷ ²⁰⁸ 40 mg once daily may be required.² ⁹⁸ May give an additional 4 weeks of therapy (up to 12 weeks for a single course).¹ ² ⁹⁸ ²⁰⁷ If recurs, consider additional 4–8 weeks of therapy.¹ ²⁰⁷

Maintenance of Healing of Erosive Esophagitis

Oral (Immediate-release Capsules or Oral Suspension, Delayed-release Capsules or Oral Suspension)

20 mg once daily.¹ ²⁰⁷ ²⁰⁸ Chronic, lifelong therapy may be appropriate.¹⁴³

Self-medication for Frequent Heartburn

Oral (Delayed-release Tablets)

20 mg daily in the morning for 14 days.¹⁸⁷ ¹⁸⁸ Do not exceed recommended dosage or duration; do not administer more than one course every 4 months.¹⁸⁷ ¹⁸⁸ May relieve symptoms within 24 hours, but 1–4 days may be required for complete relief.¹⁸⁷ ¹⁸⁸ ¹⁸⁹

Duodenal Ulcer

Treatment of Active Duodenal Ulcer

Oral (Immediate-release Capsules or Oral Suspension, Delayed-release Capsules or Oral Suspension)

20 mg once daily until healing occurs (usually within 2–4 weeks); an additional 4 weeks with therapy may be beneficial.¹ ² ²⁰⁷ ²⁰⁸ Patients who responded poorly to histamine H₂-receptor antagonists may require up to 40 mg daily.²

Treatment of Helicobacter pylori Infection and Duodenal Ulcer

Oral (Delayed-release Capsules or Oral Suspension)

Triple therapy: 20 mg twice daily (morning and evening) for 10 days in conjunction with amoxicillin and clarithromycin; additional omeprazole therapy with 20 mg once daily for 18 days recommended if active ulcer present initially.¹

Dual therapy: 40 mg once daily (in the morning) for 14 days in conjunction with clarithromycin; omeprazole 20 mg once daily for additional 14 days recommended if active ulcer present initially.¹

Gastric Ulcer

Treatment

Oral (Immediate-release Capsules or Oral Suspension, Delayed-release Capsules or Oral Suspension)

40 mg once daily for 4–8 weeks.¹ ²⁰⁷ ²⁰⁸

Pathologic GI Hypersecretory Conditions

Zollinger-Ellison Syndrome

Oral (Delayed-release Capsules or Delayed-release Oral Suspension)

60 mg once daily initially.¹ ² Adjust dosage according to patient response and tolerance; continue therapy as long as necessary.¹ ² ¹³ Administer daily dosages >80 mg in divided doses.¹ ¹³ May require dosages of up to 360 mg daily (given in 3 divided doses).¹ ²

Multiple Endocrine Adenomas

Oral (Delayed-release Capsules or Delayed-release Oral Suspension)

Systemic Mastocytosis

Oral (Delayed-release Capsules or Delayed-release Oral Suspension)

Upper GI Bleeding

Reduction of Risk of Upper GI Bleeding in Critically Ill Adults

Oral (Immediate-release Oral Suspension)

Initially, 40 mg followed by 40 mg after 6–8 hours on the first day, then 40 mg once daily for up to 14 days.²⁰⁷ Safety and efficacy for >14 days not established.²⁰⁷

Special Populations

Hepatic Impairment

Consider dosage reduction, particularly in patients receiving long-term therapy for maintenance of healing of erosive esophagitis.¹ ²⁰⁷

Renal Impairment

No dosage adjustment necessary.¹ ²⁰⁷

Asians

Consider dosage reduction, especially in patients receiving long-term therapy for maintenance of healing of erosive esophagitis.¹ ²⁰⁷

Cautions for Omeprazole

Contraindications

Known hypersensitivity to omeprazole, any ingredient in the formulation, or esomeprazole or other substituted benzimidazoles (e.g., lansoprazole, pantoprazole, rabeprazole).¹ ²⁵ ¹³⁹ ²⁰⁷

Warnings/Precautions

Sensitivity Reactions

Hypersensitivity Reactions

Hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, interstitial nephritis, urticaria) reported.¹

Warnings/Precautions

Gastric Malignancy

Response to omeprazole does not preclude presence of occult gastric neoplasm.¹ ²⁰⁷ ²⁰⁸

Atrophic Gastritis

Atrophic gastritis reported occasionally with long-term use.¹ ²⁰⁷ ²⁰⁸

Clostridium difficile Infection

Proton-pump inhibitors associated with possible increased (1.4–2.75 times) risk of Clostridium difficile infection, including C. difficile-associated diarrhea and colitis (CDAD; also known as antibiotic-associated diarrhea and colitis or pseudomembranous colitis).³³⁵ ³³⁶ ³³⁹ ³⁴⁰ Many patients also had other risk factors for CDAD.³³⁵ May be severe; colectomy and, rarely, death reported.³³⁵

Use the lowest effective dosage and shortest duration of therapy appropriate for the patient's clinical condition.³³⁵

Consider CDAD if persistent diarrhea develops and manage accordingly; initiate supportive therapy (e.g., fluid and electrolyte management), anti-infective therapy directed against C. difficile (e.g., metronidazole, vancomycin), and surgical evaluation as clinically indicated.³³⁵ ³³⁶

Sodium Bicarbonate

Each 20- and 40- mg conventional immediate-release capsule contains 1100 mg of sodium bicarbonate (304 mg [13 mEq] of sodium), and each 20- and 40-mg single-dose packet of powder for immediate-release oral suspension contains 1680 mg of sodium bicarbonate (460 mg [20 mEq] of sodium).²⁰⁷ Consider sodium content when used in patients requiring restricted salt intake.²⁰⁷

Caution in patients with Bartter’s syndrome, hypokalemia, respiratory alkalosis, and acid-base abnormalities.²⁰⁷ ²⁰⁸ Long-term administration of sodium bicarbonate with calcium or milk may cause milk-alkali syndrome.²⁰⁷ Long-term use of sodium bicarbonate may lead to systemic alkalosis, and increased sodium intake can produce edema and weight increase.²⁰⁷ Sodium bicarbonate is contraindicated in patients with metabolic alkalosis or hypocalcemia.²⁰⁸

Respiratory Effects

Administration of proton-pump inhibitors has been associated with an increased risk for developing certain infections (e.g., community-acquired pneumonia).¹⁹⁹ ²⁰⁰

Bone Fracture

Several observational studies suggest that use of proton-pump inhibitors, particularly in high dosages (i.e., multiple daily doses) and/or for prolonged periods of time (i.e., ≥1 year), may be associated with increased risk of osteoporosis-related fractures of the hip, wrist, or spine.¹ ²¹² ³⁰⁰ ³⁰¹ ³⁰² ³⁰³ ³⁰⁴ ³⁰⁵ Magnitude of risk is unclear;²¹² ³⁰⁰ ³⁰¹ ³⁰² ³⁰³ ³⁰⁴ ³⁰⁵ ³¹⁰ causality not established.³⁰⁵ FDA is continuing to evaluate this safety concern.³⁰⁵

Use the lowest effective dosage and shortest duration of therapy appropriate for the patient’s clinical condition.¹ ²¹² ³⁰¹ ³⁰³ ³⁰⁵ ³⁰⁷

Individuals at risk for osteoporosis-related fractures should receive an adequate intake of calcium and vitamin D; assess and manage these patients’ bone health according to current standards of care.¹ ²¹² ³⁰³ ³⁰⁵ ³⁰⁷

Hypomagnesemia

In patients expected to receive long-term proton-pump inhibitor therapy or in patients currently receiving digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), consider measuring serum magnesium concentrations prior to initiation of prescription proton-pump inhibitor therapy and periodically thereafter.¹ ²⁰⁷ ³¹³ ³¹⁴ ³¹⁶ ³¹⁹ ³²⁶

Hypomagnesemia, symptomatic and asymptomatic, reported rarely in patients receiving long-term therapy (≥3 months or, in most cases, >1 year) with proton-pump inhibitors, including omeprazole.¹ ²⁰⁷ ³¹³ ³¹⁴ ³¹⁵ ³¹⁶ ³¹⁷ ³¹⁸ ³¹⁹ ³²⁰ ³²¹ ³²² ³²³ ³²⁴ ³²⁵ ³²⁶ Serious adverse effects include tetany, seizures, tremors, carpopedal spasm, arrhythmias (e.g., atrial fibrillation, supraventricular tachycardia), and abnormal QT interval.¹ ²⁰⁷ ³¹³ ³¹⁴ ³¹⁵ ³¹⁸ ³¹⁹ ³²¹ ³²² ³²³ ³²⁵ Paresthesia, muscle weakness, muscle cramps, lethargy, fatigue, and unsteadiness may occur.³¹⁶ ³¹⁹ ³²⁰ ³²¹ ³²⁵ Most patients required magnesium replacement and discontinuance of the proton-pump inhibitor.¹ ²⁰⁷ ³¹³ ³¹⁶ ³¹⁷ ³¹⁹ ³²¹ ³²² ³²³ ³²⁴ ³²⁵ ³²⁶ Hypomagnesemia resolved within 1 week (median) following discontinuance and recurred within 2 weeks (median) of rechallenge.³¹³

Cardiovascular Effects

Preliminary safety data from 2 long-term clinical trials comparing esomeprazole or omeprazole with antireflux surgery in patients with severe GERD raised concerns about a potential increased risk of cardiac events (e.g., MI, heart failure, sudden death) in patients receiving these drugs.²¹³ ²¹⁴ ²¹⁵ After reviewing data from these and other studies, FDA has concluded that long-term use of these drugs is not likely to be associated with an increased risk of such cardiac events.²¹³ ²¹⁴ ²¹⁵ FDA recommends that clinicians continue to prescribe and patients continue to use these drugs in the manner described in the manufacturers’ labelings.²¹³ ²¹⁴ ²¹⁵

Specific Populations

Pregnancy

Category C.¹ ²⁰⁷ ²⁰⁸

Lactation

Distributed into milk.¹ ¹³⁹ ²⁰² ²⁰⁷ Discontinue nursing or the drug.¹ ¹³⁹ ²⁰⁷

Pediatric Use

Safety and efficacy of delayed-release capsules or delayed-release oral suspension established for treatment of symptomatic GERD, treatment of erosive esophagitis, and maintenance of healing of erosive esophagitis in pediatric patients 1–16 years of age.¹ ¹⁹⁸ Safety and efficacy not established in infants <1 year of age or for other uses in pediatric patients.¹

Safety and efficacy for self-medication of frequent heartburn not established in children <18 years of age.¹⁸⁷

Safety and efficacy of immediate-release capsules or immediate-release oral suspension not established in pediatric patients <18 years of age.²⁰⁷

Geriatric Use

No substantial differences in efficacy and safety relative to younger adults, but increased sensitivity cannot be ruled out.¹ ²⁰⁷

Hepatic Impairment

Increased bioavailability and decreased clearance.¹ ²⁰⁷ Monitor patients receiving >20 mg daily for possible adverse effects.³ (See Hepatic Impairment under Dosage and Administration.)

Common Adverse Effects

In adults, diarrhea, nausea, constipation, abdominal pain, vomiting, headache, flatulence.¹ ² ³ ²⁰⁷ ²⁰⁸

In pediatric patients, respiratory effects, fever (in children 1–2 years of age), accidental injuries (in children 2–16 years of age); otherwise, adverse effects generally similar to those in adults.¹

Drug Interactions

Metabolized in the liver by CYP isoenzymes, principally CYP2C19, and to lesser extent by CYP3A4.¹ ¹³⁹ Inhibits CYP2C19.¹

Drugs Metabolized by Hepatic Microsomal Enzymes

Potential to prolong elimination of drugs metabolized by oxidation in the liver.¹ ² ²⁰⁷ Interaction reported with drugs metabolized by CYP isoenzymes; monitor and adjust dosage of these drugs if necessary.¹ ²⁰⁷

Drugs that Cause Hypomagnesemia

Potential pharmacologic interaction (possible increased risk of hypomagnesemia).³¹³ Consider monitoring magnesium concentrations prior to initiation of prescription proton-pump inhibitor therapy and periodically thereafter.¹ ³¹³ (See Hypomagnesemia under Cautions.)

Specific Drugs

Drug	Interaction	Comments
Atazanavir	Possible altered oral absorption of atazanavir, resulting in decreased plasma atazanavir concentrations; possible loss of virologic response¹ ²⁰⁷ ²¹⁸	Manufacturers of omeprazole state that concomitant use with atazanavir is not recommended¹ ²⁰⁷ Antiretroviral treatment-naive patients: If a proton-pump inhibitor is used concomitantly with atazanavir, administer ritonavir-boosted atazanavir (atazanavir 300 mg and ritonavir 100 mg once daily with food); administer the proton-pump inhibitor approximately 12 hours before ritonavir-boosted atazanavir²¹⁷ ²¹⁸ For treatment-naive patients, dosage of proton-pump inhibitor should not exceed omeprazole 20 mg daily (or equivalent)²¹⁷ ²¹⁸ Antiretroviral treatment-experienced patients: Concomitant use of proton-pump inhibitors with atazanavir not recommended²¹⁷ ²¹⁸
Benzodiazepines	Potential for altered benzodiazepine metabolism¹ ²⁰⁷	Monitor and adjust benzodiazepine dosage if needed¹ ²⁰⁷
Cilostazol	Increased peak plasma concentrations and AUC of cilostazol and its active metabolite¹	Consider reducing cilostazol dosage (from 100 mg twice daily to 50 mg twice daily)¹
Clarithromycin	Increased plasma concentrations and AUC of omeprazole, clarithromycin, and 14-hydroxyclarithromycin ¹ ²⁰⁷
Clopidogrel	Omeprazole (or esomeprazole) reduces exposure to clopidogrel's active metabolite and decreases platelet inhibitory effects;¹ ²²³ ²²⁴ ²²⁵ ²²⁸ ³⁵⁰ additional data needed to fully elucidate potential clinical consequences (e.g., increased cardiovascular events)²³⁰ ²³⁶ ²³⁷ ²⁴⁰ ²⁴³ ²⁴⁴ ²⁴⁵ ²⁴⁶ ²⁴⁷ ²⁴⁸ ²⁴⁹ ²⁵⁰ ²⁵¹ ²⁵² Dexlansoprazole, lansoprazole, or pantoprazole had less effect on clopidogrel's antiplatelet activity than did omeprazole or esomeprazole²²⁴ ³⁵⁰ ³⁵¹	Avoid concomitant use of omeprazole (or esomeprazole) and clopidogrel¹ ²²⁴ ²³² ²³³ ³¹² Assess risks and benefits of concomitant proton-pump inhibitor use in individual patients²³⁷ ²⁴⁰ ²⁴³ ²⁴⁸ ²⁵⁰ ³¹¹ American College of Cardiology Foundation/American College of Gastroenterology/American Heart Association (ACCF/ACG/AHA) states that GI bleeding risk reduction with concomitant proton-pump inhibitor in patients with risk factors for GI bleeding (e.g., advanced age; concomitant use of warfarin, corticosteroids, or NSAIAs; H. pylori infection) may outweigh potential reduction in cardiovascular efficacy of antiplatelet treatment associated with a drug-drug interaction.³¹¹ In patients without such risk factors, ACCF/ACG/AHA states that risk/benefit balance may favor use of antiplatelet therapy without a proton-pump inhibitor.³¹¹ If concomitant therapy with a proton-pump inhibitor and clopidogrel is deemed necessary, consider using an agent with little or no CYP2C19-inhibitory activity;²²³ ²³⁰ ²³⁴ ³¹² ³⁵⁰ alternatively, consider using a histamine H₂-receptor antagonist (ranitidine, famotidine, nizatidine)²²³ ²²⁴ ²³⁰ ²³⁴ ²⁵¹ but not cimetidine (also a potent CYP2C19 inhibitor)²³² ²³³
Cyanocobalamin	Potential for decreased cyanocobalamin absorption⁸⁶ ⁹⁸ ⁹⁹ ¹⁰⁰ ¹⁰¹	Monitor serum cyanocobalamin concentrations during long-term omeprazole therapy⁹⁹
Cyclosporine	Potential for altered cyclosporine metabolism¹ ²⁰⁷	Monitor and adjust cyclosporine dosage if needed¹ ²⁰⁷
Darunavir	Ritonavir-boosted darunavir: Decreased plasma concentrations of omeprazole; no effect on darunavir concentrations²¹⁷	Ritonavir-boosted darunavir: No dosage adjustments required³⁴⁹
Diazepam	Potential for prolonged diazepam elimination¹ ²⁰⁷
Digoxin	Increased digoxin bioavailability¹ Hypomagnesemia (e.g., resulting from long-term use of proton-pump inhibitors) sensitizes the myocardium to digoxin and, thus, may increase risk of digoxin-induced cardiotoxic effects³¹³ ³³¹	Monitor for manifestations of digoxin toxicity¹ Consider monitoring magnesium concentrations prior to initiation of prescription proton-pump inhibitor therapy and periodically thereafter¹ ³¹³
Disulfiram	Potential for altered disulfiram metabolism¹ ²⁰⁷	Monitor and adjust disulfiram dosage if needed¹ ²⁰⁷
Diuretics (i.e., loop or thiazide diuretics)	Possible increased risk of hypomagnesemia³¹³	Consider monitoring magnesium concentrations prior to initiation of prescription proton-pump inhibitor therapy and periodically thereafter¹ ³¹³
Fosamprenavir	Fosamprenavir with esomeprazole: Increased esomeprazole AUC; did not substantially alter concentrations of amprenavir (active metabolite of fosamprenavir)³⁴⁵ Ritonavir-boosted fosamprenavir with esomeprazole: Did not substantially affect amprenavir or esomeprazole concentrations³⁴⁵	No dosage adjustment required when proton-pump inhibitors used with fosamprenavir (with or without ritonavir)²¹⁷ ³⁴⁵
Gastric pH-dependent drugs (e.g., ampicillin esters, erlotinib, iron salts, ketoconazole)	Omeprazole may alter drug absorption¹ ²⁰⁷
Lopinavir	Lopinavir/ritonavir: No clinically important effect on lopinavir plasma concentrations or AUC²¹⁷ ³⁴⁴	Lopinavir/ritonavir: No dosage adjustment required when proton-pump inhibitors used concomitantly²¹⁷
Methotrexate	Possible delayed clearance and increased serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate; possible methotrexate toxicity¹ ³³³ ³³⁴ Reported mainly with high-dose methotrexate (300 mg/m² to 12 g/m²),¹ ³³³ but also reported with low dosages (e.g., 15 mg per week)³³³	Manufacturer of omeprazole recommends considering temporary discontinuance of proton-pump inhibitor therapy in some patients receiving high-dose methotrexate¹ Some clinicians recommend withholding the proton-pump inhibitor for several days before and after administration of either high-dose or low-dose methotrexate or, alternatively, substituting a histamine H₂-receptor antagonist for the proton-pump inhibitor³³³ ³³⁴
Nelfinavir	Decreased peak serum concentrations and AUC of nelfinavir and its active metabolite¹ ²⁰⁷ ³⁴⁷	Concomitant use not recommended¹ ²⁰⁷
Phenytoin	Potential for prolonged phenytoin elimination¹ ²⁰⁷
Raltegravir	Increased peak plasma concentration and AUC of raltegravir²¹⁷ ³⁴⁸	No dosage adjustment recommended²¹⁷ ³⁴⁸
Rifampin	Potential for decreased omeprazole concentrations¹	Avoid concomitant use¹
Rilpivirine	Decreased plasma concentrations and AUC of rilpivirine²¹⁷ ³⁴³	Concomitant use contraindicated²¹⁷ ³⁴³
Saquinavir	Ritonavir-boosted saquinavir: Increased peak serum concentrations and AUC of saquinavir¹ ²⁰⁷ ²¹⁷	Ritonavir-boosted saquinavir: Monitor for manifestations of saquinavir toxicity; consider reducing saquinavir dosage ¹ ²⁰⁷ ²¹⁷
St. John’s wort (Hypericum perforatum)	Decreased peak serum concentrations and AUC of omeprazole¹	Avoid concomitant use¹
Sucralfate	Possible delayed proton-pump inhibitor absorption and decreased bioavailability¹³⁴	Administer proton-pump inhibitor at least 30 minutes before sucralfate¹³⁴
Tacrolimus	Potential for increased tacrolimus concentrations¹ ²⁰⁷
Tests for neuroendocrine tumors	Increased serum chromogranin A (CgA) concentrations (secondary to omeprazole-induced increase in intragastric pH) may produce false-positive results¹	Temporarily discontinue omeprazole before assessing CgA concentrations and consider repeating test if initial CgA concentrations are high¹
Tipranavir	Ritonavir-boosted tipranavir: Decreased omeprazole plasma concentrations; no effect on tipranavir concentrations²¹⁷	Ritonavir-boosted tipranavir: Increased omeprazole dosage may be required²¹⁷
Voriconazole	Increased peak plasma concentrations and AUC of omeprazole¹ ²⁰⁷	Omeprazole dosage adjustment usually not required but may be considered in patients receiving high dosages (up to 240 mg daily), such as those with Zollinger-Ellison syndrome¹ ²⁰⁷
Warfarin	Potential for decreased warfarin metabolism and changes in prothrombin measures¹ ¹³⁴ ¹³⁹ ²⁰⁷	Monitor prothrombin time and INR¹ ¹³⁴ ¹³⁹ ²⁰⁷

Omeprazole Pharmacokinetics

Absorption

Bioavailability

Absolute bioavailability with 20–40 mg dose is about 30–40%.¹ ²⁰⁷ Bioavailability increases slightly with repeated dosing.¹ ²⁰⁷

Following administration of delayed-release oral suspension, peak concentration and AUC are 88 and 87%, respectively, of values achieved after oral administration of delayed-release capsules.¹

In children 2–5 years of age, AUCs were lower than in children 6–16 years of age or in adults.¹

Onset

Within 1 hour; maximum effect within 2 hours.¹

Duration

Duration of secretion inhibition is up to 72 hours; inhibition is 50% of maximum at 24 hours.¹ Inhibition increases with repeated daily dosing, reaching steady-state plateau at 4 days.¹ After discontinuance, gastric secretion gradually increases over 3–5 days.¹

Food

Rate of absorption is decreased with meals.³ ⁵ Most effective given about 30 minutes before a meal;⁵ ¹⁰⁸ ¹³² bioavailability may be unaffected if given up to 2 minutes before a meal.³

Administration of immediate-release oral suspension 1 hour after a meal decreases peak plasma concentrations (by 62%) and AUCs (by 26%).²⁰⁷ ²⁰⁸

Special Populations

In patients with chronic hepatic disease, bioavailability is increased to 100% due to decreased first-pass effect.¹ ²⁰⁷

In Asians, AUCs increased 4-fold after a 20-mg dose.¹ ²⁰⁷

Distribution

Extent

Omeprazole crosses the placenta and is distributed into milk.¹ ¹³⁹ ²⁰² ²⁰⁷ ²⁰⁹ ²¹⁰

Prolonged binding to gastric parietal proton pump enzyme.¹ ²⁰⁷

Plasma Protein Binding

95%.¹ ²⁰⁷

Elimination

Metabolism

Undergoes first-pass metabolism.¹ ²⁰⁷ Metabolized to inactive metabolites in the liver by CYP isoenzymes, principally CYP2C19, and to lesser extent by CYP3A4.¹ ¹³⁹

Elimination Route

Excreted principally in urine (77%) as metabolites and to a lesser extent in feces.¹ ²⁰⁷

Half-life

0.5–1 hour.¹ ²⁰⁷

Special Populations

In patients with chronic hepatic disease, clearance is decreased, and plasma half-life is increased to almost 3 hours.¹ ²⁰⁷

Stability

Storage

Oral

Delayed-release Capsules

Tight, light-resistant containers at 15–30°C.¹

Immediate-release Capsules

25°C (may be exposed to 15–30°C).²⁰⁷

Powder for Delayed-release or Immediate-release Suspension

Single-dose packets: 25°C (may be exposed to 15–30°C).¹ ²⁰⁷

Tablets for Self-medication

Tight containers at 20–25°C; protect from high heat, humidity, and moisture.¹⁸⁷

Actions

Inhibits basal and stimulated gastric acid secretion.¹ ² ³ ⁴ ⁵ ²⁰⁷
Concentrates in acid conditions of parietal cell secretory canaliculi; forms active sulfenamide metabolite that irreversibly binds to and inactivates hydrogen-potassium ATPase (proton- or acid pump),² ³ ⁵ ¹³² blocking final step in secretion of hydrochloric acid.¹ ² ³ ⁴ ⁵ ⁸ ¹³² ²⁰⁷ Acid secretion inhibited until additional hydrogen-potassium ATPase is synthesized, resulting in prolonged duration of action.² ³ ⁴ ⁵ ⁸ ¹³²
Suppresses H. pylori in patients with duodenal ulcer and/or reflux esophagitis infected with the organism.² Combined therapy with omeprazole and 1 or more appropriate anti-infectives (e.g., amoxicillin, clarithromycin) can effectively eradicate H. pylori gastric infection.¹ ² ⁶⁷ ⁹⁸ ¹³⁸

Advice to Patients

Importance of swallowing delayed-release capsule intact, without crushing or chewing.¹ Importance of taking delayed-release capsule at least 1 hour before a meal.¹
If mixed with applesauce, importance of mixing delayed-release capsule contents with applesauce soft enough to swallow without chewing.¹ Importance of not using hot applesauce.¹ Importance of immediately swallowing mixture with a glass of cool water, without crushing or chewing; importance of not storing for later use.¹
Importance of swallowing immediate-release capsule intact with water and not with other fluid.²⁰⁷ Importance of not opening capsule or mixing the contents with food.²⁰⁷
Importance of taking immediate-release capsule and oral suspension at least 1 hour before a meal.²⁰⁷ ²⁰⁸
Importance of not substituting two 20-mg immediate-release capsules for one 40-mg capsule or two 20-mg powder for immediate-release oral suspension packets for one 40-mg packet.²⁰⁷
Importance of mixing powder for oral suspension in small cup with water, not with other fluids or food.¹ ²⁰⁷ ²⁰⁸ Importance of swallowing suspension immediately, then refilling cup with water and swallowing to ensure complete ingestion of dose.¹ ²⁰⁷ ²⁰⁸
Possible increased risk of Clostridium difficile infection; importance of contacting a clinician if persistent watery stools, abdominal pain, and fever occur.³³⁵
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.¹ Antacids may be used concomitantly with delayed-release capsules or oral suspension as needed for pain relief.¹ Antacids, antacids/alginic acid combinations, histamine H₂-receptor antagonists, or histamine H₂-receptor antagonist and antacid combinations may be used in conjunction with immediate-release oral suspension for “breakthrough” symptoms.²⁰⁸
Importance of advising patients that use of multiple daily doses of the drug for an extended period of time may increase the risk of fractures of the hip, wrist, or spine.¹ ³⁰⁵
Risk of hypomagnesemia; importance of immediately reporting and seeking care for any cardiovascular or neurologic manifestations (e.g., palpitations, dizziness, seizures, tetany).¹ ²⁰⁷
Importance of women informing their clinicians if they are or plan to become pregnant or plan to breast-feed.¹
Importance of following dosage instructions when omeprazole magnesium is administered for self-medication.¹⁸⁷ ¹⁸⁸ Advise patients that they should use the drug for self-medication only as directed for no longer than 14 days of continuous use and that they should not exceed one course of therapy every 4 months.³⁰⁵
Importance of discontinuing use as self-medication and consulting a clinician if heartburn persists or worsens, use of the drug for >14 days is needed, or >1 course of therapy is required every 4 months.¹⁸⁷
Self-medication with omeprazole magnesium is not intended for immediate relief of heartburn; may relieve symptoms within 24 hours, but 1–4 days may be required for complete relief.¹⁸⁷ ¹⁸⁸ ¹⁸⁹ Not intended to treat occasional (e.g., occurring once weekly or less) symptoms or to prevent occasional meal- or beverage-induced heartburn.¹⁸⁷ ¹⁸⁹
Advise patients to consult their clinician before using omeprazole magnesium for self-medication if they have had heartburn for >3 months or are experiencing heartburn with lightheadedness, dizziness, or sweating; chest or shoulder pain with shortness of breath, sweating, lightheadedness, or pain spreading to the arms, neck, or shoulders; frequent chest pain; frequent wheezing (especially with heartburn); unexplained weight loss; nausea or vomiting; or stomach pain.¹⁸⁷
Advise patients not to use omeprazole magnesium for self-medication and to consult a clinician if they have difficulty or pain with swallowing, are vomiting blood, or have bloody or blackened stools.¹⁸⁷
Importance of informing patients of other important precautionary information. (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Omeprazole
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Capsules	20 mg	Zegerid	Santarus
		40 mg	Zegerid	Santarus
	Capsules, delayed-release (containing enteric-coated granules)	10 mg*	Omeprazole Delayed-release Capsules
			PriLOSEC	AstraZeneca
		20 mg*	Omeprazole Delayed-release Capsules
			PriLOSEC	AstraZeneca
		40 mg*	Omeprazole Delayed-release Capsules
			PriLOSEC	AstraZeneca
	For suspension, powder	20 mg/packet	Zegerid	Santarus
		40 mg/packet	Zegerid	Santarus

Omeprazole Magnesium
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	For suspension, delayed-release (containing enteric-coated granules)	2.5 mg (of omeprazole) per packet	PriLOSEC	AstraZeneca
		10 mg (of omeprazole) per packet	PriLOSEC	AstraZeneca
	Tablets, delayed-release	20 mg (of omeprazole)	PriLOSEC OTC	Procter & Gamble

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. AstraZeneca. Prilosec (omeprazole) delayed-release capsules and Prilosec (omeprazole magnesium) for delayed-release oral suspension prescribing information. Wilmington, DE; 2012 Jan.

2. McTavish D, Buckley MMT, Heel RC. Omeprazole: an updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs. 1991; 42:138-70. https://pubmed.ncbi.nlm.nih.gov/1718683

3. Massoomi F, Savage J, Destache CJ. Omeprazole: a comprehensive review. Pharmacotherapy. 1993; 13:46- 59. https://pubmed.ncbi.nlm.nih.gov/8437967

4. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet. 1991; 20:38-49. https://pubmed.ncbi.nlm.nih.gov/2029801

5. Shamburek RD, Schubert ML. Pharmacology of gastric acid inhibition. Balilliere’s Clin Gastroenterol. 1993; 7:23-54.

6. Graham DY, McCullough A, Sklar M et al. Omeprazole versus placebo in duodenal ulcer healing: the United States experience. Dig Dis Sci. 1990; 35:66-72. https://pubmed.ncbi.nlm.nih.gov/2403908

7. Bardhan KD, Naesdal J, Porro GB et al. Treatment of refractory peptic ulcer with omeprazole or continued H² receptor antagonists: a controlled clinical trial. Gut. 1991; 32:435-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1379086/ https://pubmed.ncbi.nlm.nih.gov/1673953

8. Maton PN. Omeprazole. N Engl J Med. 1991; 324:965-75. https://pubmed.ncbi.nlm.nih.gov/2002819

9. Bardhan KD, Porro GB, Bose K et al. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. J Clin Gastroenterol. 1986; 8:408- 13. https://pubmed.ncbi.nlm.nih.gov/3531313

10. Van Deventer. Gastroenterology. 1988; 94. Abstract No. 476.

11. Graham DY, Colon-Pagan J, Morse RS et al. Ulcer recurrence following duodenal ulcer healing with omeprazole, ranitidine, or placebo: a double-blind, multicenter 6-month study. Gastroenterology. 1992; 102:1289-94. https://pubmed.ncbi.nlm.nih.gov/1551535

12. Sontag SJ, Hirschowitz BI, Holt S et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. multicenter study. Gastroenterology. 1992; 102:109-118. https://pubmed.ncbi.nlm.nih.gov/1727744

13. Maton PN, Vinayek R, Frught H et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology. 1989; 97:827-36. https://pubmed.ncbi.nlm.nih.gov/2777040

14. Lee ML, Piper D, Fischer GO et al. Lichen spinulosus after the ingestion of omeprazole. Med J Aust. 1989; 150:410. https://pubmed.ncbi.nlm.nih.gov/2716669

15. Marks DR, Joy JV, Bonheim NA. Hemolytic anemia associated with the use of omeprazole. Am J Gastroenterol. 1991; 86:217-8. https://pubmed.ncbi.nlm.nih.gov/1992636

16. Ruffenach SJ, Siskind M, Lien YHH. Acute interstitial nephritis due to omeprazole. Am J Med. 1992; 93:472- 3. https://pubmed.ncbi.nlm.nih.gov/1341422

17. Kuiper JJ. Omeprazole-induced acute interstitial nephritis. Am J Med. 1993; 95:248. https://pubmed.ncbi.nlm.nih.gov/8356994

18. Nasser K, Irshad M, Howden CW. Prevalence of male sexual dysfunction during treatment with omeprazole. Gastroenterology. 1992; 102(Suppl 2/2):133.

19. Dutertre JP, Soutif D, Jonville AP et al. Sexual disturbances during omeprazole therapy. Lancet. 1991; 338:1022. https://pubmed.ncbi.nlm.nih.gov/1681330

20. Santucci L, Farroni F, Fiorucci S et al. Gynecomastia during omeprazole therapy. N Engl J Med. 1991; 324:635. https://pubmed.ncbi.nlm.nih.gov/1992328

21. Jochem V, Kirkpatrick R, Greenson J et al. Fulminant hepatic failure related to omeprazole. Am J Gastroenterol. 1992; 87:523-5. https://pubmed.ncbi.nlm.nih.gov/1553942

22. Lamberts R, Creutzfeldt W, Struber HG et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology. 1993; 104:1356-70. https://pubmed.ncbi.nlm.nih.gov/8482449

23. Cox NH. Acute disseminated epidermal necrosis due to omeprazole. Lancet. 1992; 340:857. https://pubmed.ncbi.nlm.nih.gov/1357283

24. Christensen PB, Albertsen KEP, Jensen P. Renal failure after omeprazole. Lancet. 1993; 341:55. https://pubmed.ncbi.nlm.nih.gov/8093302

25. Haeney MR. Angio-oedema and uricaria associated with omeprazole. BMJ. 1992; 305:870. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1883085/ https://pubmed.ncbi.nlm.nih.gov/1422401

26. Landahl S, Andersson T, Larsson M et al. Pharmacokinetic study of omeprazole in elderly healthy volunteers. Clin Pharmacokinet. 1992; 23:469-76. https://pubmed.ncbi.nlm.nih.gov/1458764

27. Ateshkadi A, Lam NP, Johnson CA. Helicobacter pylori and peptic ulcer disease. Clin Pharm. 1993; 12:34-48. https://pubmed.ncbi.nlm.nih.gov/8428432

28. Blaser MJ. Helicobacter pylori: its role in disease. Clin Infect. 1992; 15:386-91.

29. Marshall BJ. Treatment strategies for Helicobacter pylori infection. Gastroenterol Clin North Am. 1993; 22:183-98. https://pubmed.ncbi.nlm.nih.gov/8449566

30. Israel DM, Hassall E. Treatment and long-term follow-up of Helicobacter pylori-associated duodenal ulcer disease in children. J Pediatr. 1993; 123:53-8. https://pubmed.ncbi.nlm.nih.gov/8320625

31. Murray DM, DuPont HL, Cooperstock M et al. Evaluation of new anti-infective drugs for the treatment of gastritis and peptic ulcer disease associated with infection by Helicobacter pylori. Clin Infect Dis. 1992; 15(Suppl 1):S268-73.

32. Chiba N, Rao BV, Rademaker JW et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol. 1992; 87:1716-27. https://pubmed.ncbi.nlm.nih.gov/1449132

33. Glassman MS. Helicobacter pylori infection in children. A clinical overview. Clin Pediatr (Phila). 1992; 31:481-7. https://pubmed.ncbi.nlm.nih.gov/1643767

34. Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med. 1991; 324:1043-8. https://pubmed.ncbi.nlm.nih.gov/2005942

35. Logan RP, Gummett PA, Misiewicz JJ et al. One week eradication regimen for Helicobacter pylori. Lancet. 1991; 338:1249-52. https://pubmed.ncbi.nlm.nih.gov/1682653

36. Burette A, Glupczynski Y. On: The who’s and when’s of therapy for Helicobacter pylori. 1991; 86:924-5. Letter.

37. Bayerdorffer E, Mannes GA, Sommer A et al. Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. Scand J Gastroenterol Suppl. 1993; 196:19-25. https://pubmed.ncbi.nlm.nih.gov/8341987

38. Unge P, Ekstrom P. Effects of combination therapy with omeprazole and an antibiotic on H. pylori and duodenal ulcer disease. Scand J Gastroenterol Suppl. 1993; 196:17-8.

39. Hunt RH. Hp and pH: implications for the eradication of Helicobacter pylori. Scand J Gastroenterol Suppl. 1993; 196:12-6. https://pubmed.ncbi.nlm.nih.gov/8341986

40. Malfertheiner P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol Suppl. 1993; 196:34-7. https://pubmed.ncbi.nlm.nih.gov/8341989

41. Bell GD, Powell U. Eradication of Helicobacter pylori and its effect in peptic ulcer disease. Scand J Gastroenterol Suppl. 1993; 196:7-11. https://pubmed.ncbi.nlm.nih.gov/8341990

42. Adamek RJ, Wegener M, Opferkuch W et al. Successful Helicobacter pylori eradication: a systemic effect of antibiotics? Am J Gastroenterol. 1993; 88:792-3. Letter.

43. Bianchi Porro G, Parente F, Lazzaroni M. Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone. Gut. 1993; 34:466-9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1374304/ https://pubmed.ncbi.nlm.nih.gov/8491391

44. Graham DY, Go MF. Evaluation of new antiinfective drugs for Helicobacter pylori infection: revisited and updated. Clin Infect Dis. 1993; 17:293-4. https://pubmed.ncbi.nlm.nih.gov/8399892

45. Murray DM, DuPont HL. Reply. (Evaluation of new antiinfective drugs for Helicobacter pylori infection: revisited and updated.) Clin Infect Dis. 1993; 17: 294-5.

46. George LL, Borody TJ, Andrews P et al. Cure of duodenal ulcer after eradication of H. pylori. Med J Aust. 1990; 153:145-9. https://pubmed.ncbi.nlm.nih.gov/1974027

47. Farrell MK. Dr. Apley meets Helicobacter pylori. J Pediatr Gastroenterol Nutr. 1993; 16:118-9. https://pubmed.ncbi.nlm.nih.gov/8450375

48. Fiocca R, Solcia E, Santoro B. Duodenal ulcer relapse after eradication of Helicobacter pylori. Lancet. 1991; 337:1614. https://pubmed.ncbi.nlm.nih.gov/1675746

49. Marshall BJ. Campylobacter pylori: its link to gastritis and peptic ulcer disease. Clin Infect Dis. 1990; 12(Suppl 1):S87-93.

50. Nomura A, Stemmermann GN, Chyou PH et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991; 325:1132-6. https://pubmed.ncbi.nlm.nih.gov/1891021

51. Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991; 325:1127-31. https://pubmed.ncbi.nlm.nih.gov/1891020

52. An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet. 1993; 341:1359-62. https://pubmed.ncbi.nlm.nih.gov/8098787

53. Talley NJ, Zinsmeister AR, Weaver A et al. Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst. 1991; 83:1734-9. https://pubmed.ncbi.nlm.nih.gov/1770552

54. Forman D, Newell DG, Fullerton F et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991; 302:1302-5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1670011/ https://pubmed.ncbi.nlm.nih.gov/2059685

55. Forman D. Helicobacter pylori infection: a novel risk factor in the etiology of gastric cancer. J Natl Cancer Inst. 1991; 83:1702-3. https://pubmed.ncbi.nlm.nih.gov/1770545

56. Parsonnet J. Helicobacter pylori and gastric cancer. Gastroenterol Clin North Am. 1993; 22:89-104. https://pubmed.ncbi.nlm.nih.gov/8449573

57. Correa P. Is gastric carcinoma an infectious disease? N Engl J Med. 1991; 325:1170-1.

58. Isaacson PG, Spencer J. Is gastric lymphoma an infectious disease? Hum Pathol. 1993; 24:569-70.

59. Borody T, Andrews P, Mancuso N et al. Helicobacter pylori reinfection 4 years post-eradication. Lancet. 1992; 339:1295. https://pubmed.ncbi.nlm.nih.gov/1349686

60. Hixson LJ, Kelley CL, Jones WN et al. Current trends in the pharmacotherapy for peptic ulcer disease. Arch Intern Med. 1992; 152:726-32. https://pubmed.ncbi.nlm.nih.gov/1558429

61. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer with eradication of Helicobacter pylori. Lancet. 1990; 335:1233-5. https://pubmed.ncbi.nlm.nih.gov/1971318

62. Hunt RH. pH and Hp—gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol. 1993; 88:481-3. https://pubmed.ncbi.nlm.nih.gov/8470623

63. Hentschel E, Brandstatter G, Dragosics B et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993; 328:308-12. https://pubmed.ncbi.nlm.nih.gov/8419816

64. Graham DY, Lew GM, Evans DG et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing: a randomized controlled trial. Ann Intern Med. 1991; 115:266-9. https://pubmed.ncbi.nlm.nih.gov/1854110

65. Reviewers’ comments (personal observations) on Helicobacter pylori; 1993 Oct 26.

66. Marshall BJ. Helicobacter pylori. Am J Gastroenterol. 1994; 89(Suppl):S116-28.

67. Labenz J, Gyenes E, Rühl GH et al. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut. 1993; 34:1167-70. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1375447/ https://pubmed.ncbi.nlm.nih.gov/8406147

68. Labenz J, Gyenes E, Rühl GH et al. Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori. Am J Gastroenterol. 1993; 88:491-5. https://pubmed.ncbi.nlm.nih.gov/8470626

69. Bell GD, Powell KU, Burridge SM et al. Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Q J Med. 1993; 86:743-50. https://pubmed.ncbi.nlm.nih.gov/8265776

70. Labenz J, Rühl GH, Bertrams J et al. Medium- and high-dose omeprazole plus amoxicillin for eradication of Helicobacter pylori in duodenal ulcer disease. Dig Dis Sci. 1994; 39:1483-7. https://pubmed.ncbi.nlm.nih.gov/8026260

71. Labenz J, Börsch G. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection. Am J Gastroenterol. 1994; 89:1785-8. https://pubmed.ncbi.nlm.nih.gov/7942667

72. Wang WM, Chen CY, Jan CM et al. Long-term follow-up and serological study after triple therapy of Helicobacter pylori-associated duodenal ulcer. Am J Gastroenterol. 1994; 89:1793-6. https://pubmed.ncbi.nlm.nih.gov/7942669

73. Savarino V, Sandro Mela G, Zentilin P et al. Acid inhibition and amoxicillin activity against Helicobacter pylori. Am J Gastroenterol. 1993; 88:1975-6. https://pubmed.ncbi.nlm.nih.gov/8237959

74. Labenz J, Börsch G. Acid inhibition and amoxicillin activity against Helicobacter pylori: response to Savarino et al. Am J Gastroenterol. 1993; 88:1976. https://pubmed.ncbi.nlm.nih.gov/8292199

75. Anon. Drugs for treatment of peptic ulcers. Med Lett Drugs Ther. 1994; 36:65-7. https://pubmed.ncbi.nlm.nih.gov/7912812

76. Freston JW. Emerging strategies for managing peptic ulcer disease. Scand J Gastroenterol Suppl. 1994; 201:49-54. https://pubmed.ncbi.nlm.nih.gov/8047824

77. Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol Suppl. 1994; 201:16-23. https://pubmed.ncbi.nlm.nih.gov/8047818

78. Labenz J, Rühl GH, Bertrams J et al. Medium- or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease. Am J Gastroenterol. 1994; 89:726-30. https://pubmed.ncbi.nlm.nih.gov/8172146

79. Labenz J, Borsch G. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut. 1994; 35:19-22. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1374625/ https://pubmed.ncbi.nlm.nih.gov/8307443

80. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA. 1994; 272:65-9. https://pubmed.ncbi.nlm.nih.gov/8007082

81. Fennerty MB. Helicobacter pylori. Ann Intern Med. 1994; 154:721-7.

82. Adamek RJ, Wegener M, Labenz J et al. Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy. Am J Gastroenterol. 1994; 89:39-42. https://pubmed.ncbi.nlm.nih.gov/8273795

83. Peura DA, Graham DY. Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease. Am J Gastroenterol. 1994; 89:1137-9. https://pubmed.ncbi.nlm.nih.gov/8053422

84. Cotton P. NIH consensus panel urges antimicrobials for ulcer patients, skeptics concur with caveats. JAMA. 1994; 271:808-9. https://pubmed.ncbi.nlm.nih.gov/8114221

85. Feldman M. The acid test. Making clinical sense of the consensus conference on Helicobacter pylori. JAMA. 1994; 272:70-1. https://pubmed.ncbi.nlm.nih.gov/8007084

86. Kemp JA, Golner BB, Russell RM. Effect of an acidic dietary drink on absorption of protein- bound vitamin B12. Gastroenterology. 1992; 102:A560.

87. Kraus A, Flores-Suárez LF. Acute gout associated with omeprazole. Lancet. 1995; 345:461-2.

88. Epelde Gonzalo FD, Montagut LB, Vecina ST. Exfoliative dermatitis related to omeprazole. Ann Pharmacother. 1995; 29:82-3.

89. Beutler M, Hartmann K, Kuhn M et al. Arthralgias and omeprazole. BMJ. 1994; 309:1620. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2541956/ https://pubmed.ncbi.nlm.nih.gov/7819941

90. Ottervanger JP, Stricker BHC, Kappelle JW et al. Omeprazole-associated agranulocytosis. Eur J Haematol. 1995; 54:279-80. https://pubmed.ncbi.nlm.nih.gov/7789474

91. Bowlby HA, Dickens GR. Angioedema and urticaria associated with omeprazole confirmed by drug rechallenge. Pharmacotherapy. 1993; 14:119-22.

92. Hallerbäck B, Unge P, Carling L et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology. 1994; 107:1305-11. https://pubmed.ncbi.nlm.nih.gov/7926494

93. Astra Merck, Wayne, PA: Personal communication.

94. Sontag S, Robinson M, Roufail W et al. Daily omeprazole (OME) is needed to maintain healing in erosive esophagitis (EE): a U.S., multicenter double-blind study. Am J Gastroenterol. 1992; 87:1258.

95. Dent J, Yeomans ND, Mackinnon M et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut. 1994; 35:590-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1374738/ https://pubmed.ncbi.nlm.nih.gov/8200548

96. Laursen LS, Bondesen S, Hansen J et al. Omeprazole 10 mg or 20 mg daily for the prevention of relapse in gastroesophageal reflux disease? A double-blind comparative study. Gastroenterology. 1992; 102:A109.

97. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994; 121:161-7. https://pubmed.ncbi.nlm.nih.gov/8017742

98. Wilde MI, McTavish D. Omeprazole: an update of its pharmacology and therapeutic use in acid-related disorders. Drugs. 1994; 48:91-132. https://pubmed.ncbi.nlm.nih.gov/7525198

99. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B₁₂). Ann Intern Med. 1994; 120:211-15. https://pubmed.ncbi.nlm.nih.gov/8273984

100. Marcuard SP. Omeprazole and vitamin B₁₂. Ann Intern Med. 1994; 121:74.

101. Anon. Correction: omeprazole and vitamin B₁₂. Ann Intern Med. 1994; 121:901.

102. Koop H, Bachem MG. Serum iron, ferritin, and vitamin B₁₂ during prolonged omeprazole therapy. J Clin Gastroenterol. 1992; 14:288-92. https://pubmed.ncbi.nlm.nih.gov/1607604

103. Barradell LB, Faulds D, McTavish D. Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs. 1992; 44:225-50. https://pubmed.ncbi.nlm.nih.gov/1382017

104. Sachs G, Shin JM, Besancon M et al. The continuing development of gastric acid pump inhibitors. Altern Pharmacol Ther. 1993; 7(Suppl 1):4-12.

105. Abbott Laboratories. Biaxin (clarithromycin) Filmtab tablets and granules for oral suspension prescribing information. Abbott Park, IL; 1996 Apr.

106. Markham A, McTavish D. Clarithromycin and omeprazole: as Helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders. Drugs. 1996; 51:161-78. https://pubmed.ncbi.nlm.nih.gov/8741237

107. Sung JJY, Chung SCS, Ling TKW et al. Dual therapy versus triple therapy for Helicobacter pylori-associated duodenal ulcers. Dig Dis Sci. 1996; 41:453-7. https://pubmed.ncbi.nlm.nih.gov/8617114

108. Soll AH. Medical treatment of peptic ulcer disease. JAMA. 1996; 275:622-9. https://pubmed.ncbi.nlm.nih.gov/8594244

109. Soll AH. Practice guidelines for treatment of peptic ulcer disease. JAMA. 1996; 276:1136-7.

110. Reviewers’ comments (personal observations) on the Aminopenicillins General Statement 8:12.16.

111. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 1995; 333:984-91. https://pubmed.ncbi.nlm.nih.gov/7666920

112. Hackelsberger A, Malfertheiner P. A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection. Drug Saf. 1996; 15:30-52. https://pubmed.ncbi.nlm.nih.gov/8862962

113. Rauws EAJ, van der Hulst RWM. Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease. Drugs. 1995; 6:984-90.

114. van der Hulst RWM, Keller JJ, Rauws EAJ et al. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1996; 1:6-19. https://pubmed.ncbi.nlm.nih.gov/9398908

115. Lind T, Veldhuyzen van Zanten S, Unge P et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter. 1996; 1:138-44. https://pubmed.ncbi.nlm.nih.gov/9398894

116. Anon. The choice of antibacterial drugs. Med Lett Drugs Ther. 1996; 38:25-34. https://pubmed.ncbi.nlm.nih.gov/8598824

117. Graham DY, Go MF. Evaluation of new antiinfective drugs for Helicobacter pylori infection: revisited and updated. Clin Infect Dis. 1993; 17:293-4. https://pubmed.ncbi.nlm.nih.gov/8399892

118. Murray DM, DuPont HL. Reply. (Evaluation of new antiinfective drugs for Helicobacter pylori infection: revisited and updated.) Clin Infect Dis. 1993; 17:294-5.

119. George LL, Borody TJ, Andrews P et al. Cure of duodenal ulcer after eradication of H. pylori. Med J Aust. 1990; 153:145-9. https://pubmed.ncbi.nlm.nih.gov/1974027

120. Farrell MK. Dr. Apley meets Helicobacter pylori. J Pediatr Gastroenterol Nutr. 1993; 16:118-9. https://pubmed.ncbi.nlm.nih.gov/8450375

121. Fiocca R, Solcia E, Santoro B. Duodenal ulcer relapse after eradication of Helicobacter pylori. Lancet. 1991; 337:1614. https://pubmed.ncbi.nlm.nih.gov/1675746

122. Marshall BJ. Campylobacter pylori: its link to gastritis and peptic ulcer disease. Clin Infect Dis. 1990; 12(Suppl 1):S87-93.

123. Graham DY, Lew GM, Klein PD et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med. 1992; 116:705-8. https://pubmed.ncbi.nlm.nih.gov/1558340

124. Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol. 1993; 88:505-9. https://pubmed.ncbi.nlm.nih.gov/8470629

125. Logan RP, Gummett PA, Hegarty BT et al. Clarithromycin and omeprazole for Helicobacter pylori. Lancet. 1992; 25:340:239.

126. Graham DY. Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med. 1993; 328:349-50. https://pubmed.ncbi.nlm.nih.gov/8419823

127. Hosking SW, Ling TK, Yung MY et al. Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. BMJ. 1992; 305:502-4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1882868/ https://pubmed.ncbi.nlm.nih.gov/1392995

128. Bell GD, Powell K, Burridge SM et al. Experience with ’triple’ anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther. 1992; 6:427-35. https://pubmed.ncbi.nlm.nih.gov/1420735

129. Fennerty MB. Practice guidelines for treatment of peptic ulcer disease. JAMA. 1996; 276:1135. Letter.

130. Abbott Laboratories, North Chicago, IL): Personal communication on Clarithromycin 8:12.12.

131. Gustavson LE, Kaiser JF, Edmonds AL et al. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother. 1995; 39:2078-83. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC162884/ https://pubmed.ncbi.nlm.nih.gov/8540719

132. Lindberg P, Brandstrom A, Wallmark B et al. Omeprazole: the first proton pump inhibitor. Medicinal Res Rev. 1990; 10:1-54.

133. Langtry HD, Wilde IW. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs. 1997; 54:1473-500.

134. TAP Pharmaceuticals, Inc. Prevacid (lansoprazole) delayed-release capsules, oral suspension, and orally disintegrating tablets prescribing information. Deerfield, IL; 2004 Jul.

135. Garnett RG. Lansoprazole: a proton pump inhibitor. Ann Pharmacother. 1996; 30:1425. https://pubmed.ncbi.nlm.nih.gov/8968456

136. Zimmerman AE, Katona BG. Lansoprazole: a comprehensive review. Pharmacotherapy. 1997; 17:308-26. https://pubmed.ncbi.nlm.nih.gov/9085323

137. Hatlebakk JG, Nesje LB, Hausken T et al. Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. Scand J Gastroenterol. 1995; 11:1053-7.

138. Salcedo JA, Al-Kawas F. Treatment of Helicobacter pylori infection. Arch Intern Med. 1998; 158:842-51. https://pubmed.ncbi.nlm.nih.gov/9570169

139. AstraZeneca, Nexium (esomeprazole magnesium) delayed-release capsules prescribing informaiton. Wilmington, DE; 2004 Nov.

140. Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs. 1998; 56:307-35. https://pubmed.ncbi.nlm.nih.gov/9777309

141. Thitiphuree S, Talley NJ. Esomeprazole, a new proton pump inhibitor: Pharmacological characteristics and clinical efficacy. Int J Clin Pract. 2000; 54:537-41. https://pubmed.ncbi.nlm.nih.gov/11198734

142. Spencer CM, Faulds D. Esomeprazole. Drugs. 2000; 60:321-9. https://pubmed.ncbi.nlm.nih.gov/10983736

143. DeVault KR, Castell DO, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 1999; 94:1434-42. https://pubmed.ncbi.nlm.nih.gov/10364004

144. Behar J, Brand DL, Brown FC et al. Cimetidine in the treatment of symptomatic gastroesophageal reflux. Gastroenterology. 1978; 74:441-8. https://pubmed.ncbi.nlm.nih.gov/340333

145. Sontag S, Robinson M, McCallum RW et al. Ranitidine therapy for gastroesophageal reflux disease. Results of a large double-blind trial. Arch Intern Med. 1987; 147: 1485-91. https://pubmed.ncbi.nlm.nih.gov/3307670

146. Euler AR, Murdock RH, Wilson TH et al. Ranitidine is effective therapy for erosive esophagitis. Am J Gastroenterol. 1993; 88:520-4. https://pubmed.ncbi.nlm.nih.gov/8470632

147. Janssen Pharmaceutica. Propulsid (cisapride monohydrate) tablets and suspension prescribing information. Titusville, NJ; 2000 Jan.

148. Klausner MA. Dear Doctor letter. Titusville, NJ: Janssen Pharmaceutica; 1995.

149. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med. 1996; 335:290-1. https://pubmed.ncbi.nlm.nih.gov/8657260

150. Lewin MB, Bryant RM, Fenrich AL et al. Cisapride-induced long QT interval. J Pediatr. 1996; 128:279-81. https://pubmed.ncbi.nlm.nih.gov/8636830

151. Bran S, Murray WA, Hirsch IB et al. Long QT syndrome during high-dose cisapride. Arch Intern Med. 1995; 155:765-8. https://pubmed.ncbi.nlm.nih.gov/7695465

152. Davis AS. The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods. Hum Exp Toxicol. 1998; 17:677-80. https://pubmed.ncbi.nlm.nih.gov/9988372

153. Chan-Tompkins NH, Babinchak TJ. Cardiac arrhythmias assocaited with coadmnistration of azole compounds and cisapride. Clin Infect Dis. 1997; 24:1285. https://pubmed.ncbi.nlm.nih.gov/9195113

154. Rampe D, Roy ML, Dennis A et al. A mechanism for the proarrhythmic effeects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. 1997; 417:28-32. https://pubmed.ncbi.nlm.nih.gov/9395068

155. AH Robins. Reglan (metoclopramide hydrochloride tablets, solution, injection) prescribing information. Richmond, VA; 2001 Sep 27.

156. Lavy S, Melamed E, Penchas S. Tardive dyskinesia associated with metoclopramide. Br Med J. 1978; 1:77-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1602611/ https://pubmed.ncbi.nlm.nih.gov/620205

157. Kataria M, Traub M, Marsden CD. Extrapyramidal side effects of metoclopramide. Lancet. 1978; 2:1254-5. https://pubmed.ncbi.nlm.nih.gov/82759

159. Stanley M, Rotrosen J, Lautin A et al. Tardive dyskinesia and metoclopramide. Lancet. 1979; 2:1190. https://pubmed.ncbi.nlm.nih.gov/91920

160. Grimes JD. Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy. N Engl J Med. 1981; 305:1417. https://pubmed.ncbi.nlm.nih.gov/7300862

161. Grimes JD, Hassan MN, Krelina M. Long-term follow-up of tardive dyskinesia due to metoclopramide. Lancet. 1982; 2:563. https://pubmed.ncbi.nlm.nih.gov/6125722

162. Ganzini L, Casey DE, Hofman WF et al. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993; 153:1469-75. https://pubmed.ncbi.nlm.nih.gov/8512437

166. Pinder RM, Brogden RN, Sawyer PR et al. Metoclopramide: a review of its pharmacological properties and clinical uses. Drugs. 1976; 12:81-131. https://pubmed.ncbi.nlm.nih.gov/786607

168. Robinson OPW. Metoclopramide: side effects and safety. Postgrad Med J. 1973; 48(Suppl 4)77-80.

169. Harrington RA, Hamilton CW, Brogden RN et al. Metoclopramide: an updated review of its pharmacological properties and clinical use. Drugs. 1983; 25:151-94.

170. Grimes JD, Hassan MN, Preston DN. Adverse neurological effects of metoclopramide. Can Med Assoc J. 1982; 126:23-5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1862808/ https://pubmed.ncbi.nlm.nih.gov/7059869

171. Banks S, Greenberg R. Alternate day omeprazole in H2 receptor-antagonist resistant reflux esophagitis. Gastroenterology. 1991; 100:A29. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2976649/ https://pubmed.ncbi.nlm.nih.gov/2001800

172. Dent J, Yeomans ND, Mackinnon M et al. Omeprazole v ranitidine for prevention of relapse in reflux esophagitis. A contolled double blind trial of their efficacy and safety. Gut. 1994; 35:590-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1374738/ https://pubmed.ncbi.nlm.nih.gov/8200548

173. Marks RD, Richter JE, Rizzo J et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology. 1994; 106:907-15. https://pubmed.ncbi.nlm.nih.gov/7848395

174. Gough AL, Long RG, Cooper BT et al. Lansoprazole vesus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther. 1996; 10:529-39. https://pubmed.ncbi.nlm.nih.gov/8853756

175. Klinkenberg-Knol EC, Festen HP, Jansen JB et al. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety. Ann Intern Med. 1994; 121:161-7. https://pubmed.ncbi.nlm.nih.gov/8017742

176. Kim SL, Waring JP, Spechler SJ et al. Effects of antireflux therapy on the extent of Barrett’s epithelium. Gastroenterology. 1993; 104:A118. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991095/ https://pubmed.ncbi.nlm.nih.gov/8500746

177. Sandmark S, Carlsson R, Fausa O et al. Omeprazole or ranitidine in the short-term treatment of ulcerative reflux esophagitis. Results of a double-blind randomized Scaninavian multicenter study. Scand J Gastroenterol. 1988; 23:625-32. https://pubmed.ncbi.nlm.nih.gov/3041558

178. Antonson CW, Robinson MG, Hawkins TM et al. High doses of histamine antagonists do not prevent relapses of peptic esophagitis following therapy with a proton pump inhibitor. Gastroenterology. 1990; 98:A16.

179. Meshkinpour H. Esophageal aperistalsis and gastroesophageal reflux disorder. Am J Gastroenterol. 1995; 90:910-4. https://pubmed.ncbi.nlm.nih.gov/7771419

180. Galmiche JP, Fraitag B, Filoche B et al. Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. Dig Dis Sci. 1990; 35:649-55. https://pubmed.ncbi.nlm.nih.gov/2331957

181. Lepoutre L, van der Speck P. Vanderlinden I et al. Healing of greade-II and III oesophagitis through motility stimulation with cisapride. Digestion. 1990; 45:109-14. https://pubmed.ncbi.nlm.nih.gov/2190850

182. Richter JE, Long JF. Cisapride for gastroesophageal reflux disease: A placebo-controlled, double-blind study. Am J Gastroenterol. 1995; 90:423-30. https://pubmed.ncbi.nlm.nih.gov/7872282

183. Lieberman DA, Keefe EB. Treatment of severe reflux esophagitis with cimetidine and metoclopramide. Ann Intern Med. 1986; 104:21-6. https://pubmed.ncbi.nlm.nih.gov/3940501

184. Galmiche JP, Brandstatter G, Evreux M et al. Combined therapy with cisapride and cimetidine in severe reflux esophagitis: A double-blind placebo-controlled trial. Gut. 1988; 29:675-81. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1433664/ https://pubmed.ncbi.nlm.nih.gov/3294124

185. Eggleston A, Wigerinck A, Huijghebaert S et al. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: A clinical database analysis. Gut. 1998; 42:13-6 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1726943/ https://pubmed.ncbi.nlm.nih.gov/9505878

186. Hilman AL, Bloom BS, Fendrick AM et al. Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease. Arch Intern Med. 1992; 152:1467-72. https://pubmed.ncbi.nlm.nih.gov/1627026

187. Procter & Gamble. Prilosec OTC (omeprazole magnesium) delayed-release tablets patient information. Cincinnati, OH; Undated. From FDA web site. http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21229lbl_Part2.pdf

188. Food and Drug Administration. Questions and answers on Prilosec OTC (omeprazole). From FDA web site. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111085.htm

189. Food and Drug Administration. Memorandum regarding citizen petition. From FDA website. http://www.fda.gov/ohrms/dockets/dailys/03/Sept03/092903/03p-0366-c000001-vol1.pdf

190. Hanauer SB, Sandborn W, and the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn’s disease in adults: Practice Guidelines. Am J Gastroenterol. 2001; 96:635-43. https://pubmed.ncbi.nlm.nih.gov/11280528

191. Valori RM, Cockel R. Omeprazole for duodenal ulceration in Crohn’s disease. Br Med J. 1990; 300:438-9.

192. Bianchi G, Ardizzone S, Petrillo M et al. Omeprazole for peptic ulcer in Crohn’s disease. Am J Gastroenterol. 1991; 86: 245-6. https://pubmed.ncbi.nlm.nih.gov/1992643

193. Przemioslo RT, Mee AS. Omeprazole in possible esophageal Crohn’s disease. Dig Dis Sci. 1994; 39:1594-5. https://pubmed.ncbi.nlm.nih.gov/8026276

194. Dickinson JB. Is omeprazole helpful in inflammatory bowel disease? J Clin Gastroenterol. 1994; 18:317-9.

195. Abrahao LJ Jr., Abrahao LJ, Vargas C et al. [Gastoduodenal Crohn’s disease—report of 4 cases and review of the literature]. (Portuguese; with English abstract.) Arq Gastroenterol. 2001; 38:57-62.

196. Freston JW. Review article: role of proton pump inhibitors in non-H. pylori-related ulcers. Aliment Pharmacol Ther. 20001; 15(Suppl 2):2-5.

197. Hassall E, Israel D, Shepard R et al. Omeprazole for the treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International pediatric omeprazole study group. J Pediatr. 2000; 137:800-7. https://pubmed.ncbi.nlm.nih.gov/11113836

198. AstraZeneca, Wilmington DE: Personal communication.

199. Laheij RJF, Sturkenboom MCJM, Hassing RJ et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955-60.

200. Gregor JC. Acid suppression and pneumonia; a clinical indication for rational prescibing. JAMA. 2004;292:2012-3. Editorial.

201. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA. 1996; 275:134-41. https://pubmed.ncbi.nlm.nih.gov/8531309

202. Omeprazole. In: Briggs GG, Freeman RK, Yaffe SJ. Drug in pregnancy and lactation: a reference guide to fetal and neonatal risk. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2002:1033-8.

203. Kallen BA. Use of omeprazole during pregnancy–no hazard demonstrated in 955 infants exposed during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2001; 96:63-8. https://pubmed.ncbi.nlm.nih.gov/11311763

204. Ruigomez A, Rodriguez LA, Cattaruzzi C et al. Use of cimetidine, omeprazole and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol. 1999; 150:476-81. https://pubmed.ncbi.nlm.nih.gov/10472947

205. Lalkin A, Loebstein R. Addis A et al. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol. 1998; 179:727-30. https://pubmed.ncbi.nlm.nih.gov/9757979

206. Kallen B. Delivery outcome after use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynaecol. 1998; 105:877-81. https://pubmed.ncbi.nlm.nih.gov/9746381

207. Santarus. Zegerid (omeprazole/sodium bicarbonate) capsules and powder for oral suspension prescribing information. San Diego, CA; 2011 May

208. Santarus. Zegerid (omeprazole) powder for oral suspension formulary dossier. San Diego, CA; 2005 Jan.

209. Moore J, Flynn RJ, Sampaio M et al. Effect of single-dose omeprazole on intragastric acidity and volume during obstetric anaesthesia. Anaesthesia. 1989; 44:559-62. https://pubmed.ncbi.nlm.nih.gov/2774120

210. Marshall JK, Thomson AB, Armstrong D. Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. Can J Gastroenterol. 1998; 12:225-7. https://pubmed.ncbi.nlm.nih.gov/9582548

211. Conrad SA, Gabrielli A, Margolis B et al. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastric bleeding in critically ill patients. Crit Care Med. 2005; 33:760-5. https://pubmed.ncbi.nlm.nih.gov/15818102

212. Yang Y-X, Lewis JD, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006; 296:2947-53. https://pubmed.ncbi.nlm.nih.gov/17190895

213. Food and Drug Administration. FDA statement: FDA’s safety reviews of Prilosec and Nexium find no evidence of increased rates of cardiac events. 2007 Dec 10. From the FDA website. Accessed 2007 Dec 21. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109037.htm

214. Food and Drug Administration. Update of safety review: follow-up to the August 9, 2007, communication about the ongoing safety review of omeprazole and esomeprazole. 2007 Dec 10. From the FDA website. Accessed 2007 Dec 21. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm143258.htm

215. Food and Drug Administration. Early communication about an ongoing safety review: omeprazole (Prilosec) and esomeprazole (Nexium). 2007 Aug 9. From the FDA website. Accessed 2007 Dec 21. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm072497.htm

216. AstraZeneca. Prilosec (omeprazole) delayed-release capsules and for delayed-release oral suspension prescribing information. Wilmington, DE; 2008 Mar.

217. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (Mar 29, 2012). From the US Department of Health and Human Services HIV/AIDS Information Services (AIDSinfo) website. http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_32.pdf

218. Bristol-Myers Squibb. Reyataz (atazanavir sulfate) capsules prescribing information. Princeton, NJ; 2012 Mar.

219. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. JACC. 2008; 51:256-60, doi:10.1016/j.jacc.2007.06.064. Accessed 2008 Dec 8. Available from website. http://content.onlinejacc.org/cgi/content/abstract/51/3/256 https://pubmed.ncbi.nlm.nih.gov/18206732

220. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. JACC. 2008; 52:1038-9. Letter. https://pubmed.ncbi.nlm.nih.gov/18786491

221. MEDCO. New study: A common class of GI medications reduce protection against heart attack in patients taking widely prescribed cardiovascular drug. Franklin Lakes, NJ; 2008 Nov 11. Press release from website. http://www.medco.com

222. Gilard M, Cornily JC, Boschat J. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. JACC. 2008; 52:1039. Reply.

223. . PPI interactions with clopidogrel revisited. Med Lett Drugs Ther. 2009; 51:13-4.

224. Sanofi-Aventis/Bristol-Myers Squibb. Plavix, (clopidogrel bisulfate) tablets prescribing information. New York, NY; 2011 Dec.

225. Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). Rockville, MD; 2009 Jan 26. From FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm079520.htm

226. Siller-Matula JM, Spiel AO, Lang IM et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009; 157:148.e1-5.

227. Gilard M, Arnaud B, Le Gal G et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006; 4:2508-9. https://pubmed.ncbi.nlm.nih.gov/16898956

228. Anon. PPI interactions with clopidogrel. Med Lett Drugs Ther. 2009; 51:2-3.

229. Aubert RE, Epstein RS, Teagarden JR et al. Proton pump inhibitors effect on clopidogrel effectiveness: The clopidogrel Medco outcomes study. Circulation. 2008; 118:S_815, Abstract 3998.

230. Lau WC, Gurbel PA. The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180:699-700. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659824/ https://pubmed.ncbi.nlm.nih.gov/19332744

231. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. Plavix, (clopidogrel bisulfate) tablets prescribing information. Bridgewater, NJ; 2009 Oct.

232. Food and Drug Administration. Information for heathcare professionals: Update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert heathcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Rockville, MD; 2009 Nov 17. From FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm190787.htm

233. Food and Drug Administration. Follow-up to the January 26, 2009 Early Communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC). Rockville, MD; 2009 Nov 17. From FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm190784.htm

234. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180:713-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659819/ https://pubmed.ncbi.nlm.nih.gov/19176635

235. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009; 301:937-44. https://pubmed.ncbi.nlm.nih.gov/19258584

236. Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009; 43:1266-74. https://pubmed.ncbi.nlm.nih.gov/19470853

237. Last EJ, Sheehan AH. Review of recent evidence: potential interaction between clopidogrel and proton pump inhibitors. Am J Health Syst Pharm. 2009; 66:2117-22. https://pubmed.ncbi.nlm.nih.gov/19923312

238. Stanek EJ, Aubert RE, Flockhart DA et al. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the Clopidogrel Medco Outcomes Study. Available from website. Accessed 2009 Dec 15. http://www.theheart.org/displayItem.do?primaryKey=967345&type=ppt

239. Dunn S, Macaulay T, Brennan D et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without use of clopidogrel in the CREDO trial. Circulation. 2008; 118:S815. Abstract 3999.

240. Stockl KM, Le L, Zakharyan A et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 2010; 170:704-10. https://pubmed.ncbi.nlm.nih.gov/20421557

241. Bhatt DL, Cryer B, Contant CF et al. The COGENT trial. Available from website. Accessed Dec 15, 2009. http://assets.cardiosource.com/Bhatt_COGENT.ppt

242. Rassen JA, Choudhry NK, Avorn J et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009; 120:2322-9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818789/ https://pubmed.ncbi.nlm.nih.gov/19933932

243. Juurlink DN. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation. 2009; 120:2310-2. https://pubmed.ncbi.nlm.nih.gov/19933929

244. Varma C. Clopidogrel and proton pump inhibitors: Are the goal posts shifting?. Thromb Res. 2009; :. https://pubmed.ncbi.nlm.nih.gov/19939439

245. Sibbing D, Morath T, Stegherr J et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009; 101:714-9. https://pubmed.ncbi.nlm.nih.gov/19350116

246. O’Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009; 374:989-97. https://pubmed.ncbi.nlm.nih.gov/19726078

247. Cuisset T, Frere C, Quilici J et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol. 2009; 54:1149-53. https://pubmed.ncbi.nlm.nih.gov/19761935

248. Khalique SC, Cheng-Lai A. Drug interaction between clopidogrel and proton pump inhibitors. Cardiol Rev. 2009 Jul-Aug; 17:198-200.

249. Kapoor JR. Impact of combining proton pump inhibitors and clopidogrel. Am J Cardiol. 2009; 103:1624. https://pubmed.ncbi.nlm.nih.gov/19463530

250. Rude MK, Chey WD. Proton-pump inhibitors, clopidogrel, and cardiovascular adverse events: fact, fiction, or something in between?. Gastroenterology. 2009; 137:1168-71. https://pubmed.ncbi.nlm.nih.gov/19635603

251. Kushner FG, Hand M, Smith SC et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009; 120:2271-306. https://pubmed.ncbi.nlm.nih.gov/19923169

252. Chua D, Lo A, Jung J. Evidence for interaction between clopidogrel and proton-pump inhibitors. Am J Health Syst Pharm. 2010; 67:604-5; author reply 605-6. https://pubmed.ncbi.nlm.nih.gov/20360584

300. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006; 79:76-83. https://pubmed.ncbi.nlm.nih.gov/16927047

301. Corley DA, Kubo A, Zhao W et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010; 139:93-101. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902649/ https://pubmed.ncbi.nlm.nih.gov/20353792

302. Yu EW, Blackwell T, Ensrud KE et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008; 83:251-9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2596870/ https://pubmed.ncbi.nlm.nih.gov/18813868

303. Gray SL, LaCroix AZ, Larson J et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010; 170:765-71. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240017/ https://pubmed.ncbi.nlm.nih.gov/20458083

304. Targownik LE, Lix LM, Metge CJ et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008; 179:319-26. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2492962/ https://pubmed.ncbi.nlm.nih.gov/18695179

305. Food and Drug Administration. Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. May 25, 2010. From FDA web site. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm

307. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010; :.

308. Targownik LE, Lix LM, Leung S et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010; 138:896-904. https://pubmed.ncbi.nlm.nih.gov/19931262

310. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008; 28:951-9. https://pubmed.ncbi.nlm.nih.gov/18657011

311. Abraham NS, Hlatky MA, Antman EM et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. JACC. 2010; 56: Published online Nov 8, 2010.

312. Food and Drug Administration. Information on clopidogrel bisulfate (marketed as Plavix). Rockville, MD; 2010 Oct 27. From FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm190836.htm

313. US Food and Drug Administration. FDA drug safety communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). Rockville, MD; 2011 March 2. From FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm

314. US Food and Drug Administration. Proton pump inhibitor drugs (PPIs): Drug safety communication- Low magnesium levels can be associated with long-term use. Rockville, MD; 2011 March 2. From FDA website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm245275.htm

315. Hoorn EJ, van der Hoek J, de Man RA et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis. 2010; 56:112-6. https://pubmed.ncbi.nlm.nih.gov/20189276

316. Regolisti G, Cabassi A, Parenti E et al. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis. 2010; 56:168-74. https://pubmed.ncbi.nlm.nih.gov/20493607

317. Furlanetto TW, Faulhaber GA. Hypomagnesemia and Proton Pump Inhibitors: Below the Tip of the Iceberg. Arch Intern Med. 2011; :. https://pubmed.ncbi.nlm.nih.gov/21555654

318. Fernández-Fernández FJ, Sesma P, Caínzos-Romero T et al. Intermittent use of pantoprazole and famotidine in severe hypomagnesaemia due to omeprazole. Neth J Med. 2010; 68:329-30. https://pubmed.ncbi.nlm.nih.gov/21071783

319. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM. 2010; 103:387-95. https://pubmed.ncbi.nlm.nih.gov/20378675

320. Shabajee N, Lamb EJ, Sturgess I et al. Omeprazole and refractory hypomagnesaemia. BMJ. 2008; 337:a425. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483862/ https://pubmed.ncbi.nlm.nih.gov/18617497

321. . In brief: PPI’s and hypomagnesemia. Med Lett Drugs Ther. 2011; 53:25.

322. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008; 69:338-41. https://pubmed.ncbi.nlm.nih.gov/18221401

323. Broeren MA, Geerdink EA, Vader HL et al. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med. 2009; 151:755-6. https://pubmed.ncbi.nlm.nih.gov/19920278

324. Metz DC, Sostek MB, Ruszniewski P et al. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol. 2007; 102:2648-54. https://pubmed.ncbi.nlm.nih.gov/17764495

325. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors--a review. Neth J Med. 2009; 67:169-72. https://pubmed.ncbi.nlm.nih.gov/19581665

326. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006; 355:1834-6. https://pubmed.ncbi.nlm.nih.gov/17065651

331. GlaxoSmithKline. Lanoxin (digoxin) tablets prescribing information. Research Triangle Park, NC; 2009 Aug.

333. Bezabeh S, Mackey AC, Kluetz P et al. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist. 2012; 17:550-4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336837/ https://pubmed.ncbi.nlm.nih.gov/22477728

334. Horn JR, Hansten PD. Methotrexate and proton pump inhibitors. Pharm Times. 2012; 78(4). Published online 2012 Apr 9. http://www.pharmacytimes.com/publications/issue/2012/April2012/Methotrexate-and-Proton-Pump-Inhibitors

335. Food and Drug Administration. Drug safety communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Rockville, MD; 2012 Feb 8. From FDA website. Accessed 2012 May 3l. http://www.fda.gov/Drugs/DrugSafety/ucm290510.htm

336. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31:431-55. https://pubmed.ncbi.nlm.nih.gov/20307191

337. Shah S, Lewis A, Leopold D et al. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM. 2000; 93:175-81. https://pubmed.ncbi.nlm.nih.gov/10751237

338. Leonard AD, Ho KM, Flexman J. Proton pump inhibitors and diarrhoea related to Clostridium difficile infection in hospitalised patients: a case-control study. Intern Med J. 2012; 42:591-4. https://pubmed.ncbi.nlm.nih.gov/22616966

339. Kwok CS, Arthur AK, Anibueze CI et al. Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis. Am J Gastroenterol. 2012; 107:1011-9. https://pubmed.ncbi.nlm.nih.gov/22525304

340. Dial S, Delaney JA, Barkun AN et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005; 294:2989-95. https://pubmed.ncbi.nlm.nih.gov/16414946

341. Nerandzic MM, Pultz MJ, Donskey CJ. Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection. Antimicrob Agents Chemother. 2009; 53:4133-7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764230/ https://pubmed.ncbi.nlm.nih.gov/19667292

343. Tibotec Therapeutics. Edurant (rilpivirine) tablets prescribing information. Raritan, NJ; 2011 May.

344. Abbott Laboratories. Kaletra (lopinavir/ritonavir) oral tablets and solution prescribing information. North Chicago, IL; 2012 May.

345. ViiV Healthcare. Lexiva (fosamprenavir calcium) tablets and oral suspension prescribing information. Research Triangle Park, NC; 2012 Apr.

347. ViiV Healthcare. Viracept (nelfinavir mesylate) tablets and oral powder prescribing information. Research Triangle Park, NC; 2012 Apr.

348. Merck Sharp & Dohme. Isentress (raltegravir) film-coated tablets and chewable tablets prescribing information. Whitehouse Station, NJ; 2012 Apr.

349. Janssen. Prezista (darunavir) prescribing information. Titusville, NJ; 2012 Jun.

350. Frelinger AL, Lee RD, Mulford DJ et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012; 59:1304-11. https://pubmed.ncbi.nlm.nih.gov/22464259

351. Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011; 89:65-74. https://pubmed.ncbi.nlm.nih.gov/20844485

352. Sanofi-Aventis/Bristol-Myers Squibb. Plavix, (clopidogrel bisulfate) tablets prescribing information. New York, NY; 2010 Mar.